Skip to main content

Table 2 Characteristics of included trials

From: Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications—a methodological review

Clinical development phase N (%)
 Phase II 12 (29)
 Phase II/III 4 (10)
 Phase III 26 (61)
Blinding N (%)
 Open label 22 (52)
 Double blind 20 (48)
Primary outcome N (%)
 Progression-free survival 27 (64)
 Overall survival 8 (19)
 Progression-free survival and overall survival 3 (7)
 Other 4 (7)
Superiority design 40 (95%)
  Median (IQR)
Number of participants randomised 364 (142–666)
Number of centres 99 (42–142)
  1. IQR interquartile range